Lumos Pharma — Q3 2020 Earnings Presentation
14 slides from Lumos Pharma's earnings presentation, Nov 10, 2020
Slide 1: Third Quarter 2020 Financial Results and Corporate Update
Third Quarter 2020 Financial Results and Corporate Update November 10, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The
Slide 3: Lumos Pharma Q3 2020 Conference Call Agenda
Lumos Pharma Q3 2020 Conference Call • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO Agenda • John McKew, PhD, COO & CSO • Eugene Kennedy, MD, CMO • Carl Langren, CFO 3
Slide 4: Clinical Development Highlights
Clinical Development Highlights • Phase 2b OraGrowtH210 Trial of LUM-201 in PGHD initiated - Data read-out anticipated mid-year 2022 • Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial of LUM-201 in PGHD remains on track - Concurrent study to begin by Q1 2021 • Lead asset, LUM-201, with pot
Slide 5: PRV sale proceeds and pipeline expansion
Corporate Update • Received first tranche, $34 million, of $60 million total proceeds owed Lumos Pharma from PRV sale - Second tranche of $26 million anticipated January 2021 • PRV proceeds represent non-dilutive funds available for pipeline expansion - Pursuit of additional rare disease assets to e
Slide 6: PGHD and Standard of Care
PGHD and Standard of Care • PGHD occurs due to inadequate secretion of growth hormone by the pituitary gland during childhood • PGHD can be either hereditary or acquired, although the majority of cases have unknown causes (idiopathic) versus - Lack of physical growth is the most obvious manifestatio
Slide 7: LUM-201 Mechanism of Action
LUM-201 Mechanism of Action GHSR1a Hypothalamus • Oral LUM-201 is a growth LUM- hormone (GH) secretagogue SST GHRH 201 • Acts as an agonist of GH GHSR1a Secretagogue Receptor Pituitary (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to GH increase the amplitude of endogenous pulsatile
Slide 8: Targeted PGHD Population
Targeted PGHD Population PEM-Positive: Included PEM-Negative: Excluded GHSR1a GHSR1a Hypothalamus HypothalamusIGF-1 SST GHRH LUM- SST GHRH LUM- 201 201 GHSR1a GHSR1a Pituitary Pituitary GH GH IGF-1 • Functional but reduced HP-GH axis • Non-functional HP-GH axis - Able to secrete some, but insufficie
Slide 9: Clinical Development Outline for PGHD
Clinical Development Outline for PGHD • Two main objectives set for Phase 2b OraGrowtH210 Trial - Prospectively confirm the utility of PEM strategy - Determine the optimal dose for Phase 3 registration trial • OraGrowtH210 Trial design - Three dose levels of LUM-201 (0.8, 1.6, 3.2 mg/kg) - Positive
Slide 10: OraGrowtH210 Trial Design
OraGrowtH210 Trial Design • Primary endpoint of the trial: preliminary clinical validation of PEM strategy intended to select subjects likely to respond to therapy with LUM-201 - Assessed by the percentage of subjects defined as PEM test positive who have a positive growth response as measured by AH
Slide 11: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD
OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD • Purpose of Pharmacokinetics/Pharmacodynamic OraGrowtH212 Trial - Further explore LUM-201’s mechanism of amplification of natural pulsatile secretion of growth hormone - To expand data package in support of future regulatory filing
Slide 12: LUM-201: Other Potential Rare Endocrine Disorders
LUM-201: Other Potential Rare Endocrine Disorders • Beyond PGHD, Prader-Willi Syndrome Small for Gestational Age rhGH FDA approved in 2000 rhGH FDA approved in 2001 Lumos Pharma also plans to investigate LUM-201 for other rare endocrine disorders, for which rhGH has been approved Idiopathic Short St
Slide 13: Secure Cash Position
Secure Cash Position Metric Position Cash balance September 30, 2020 $105.6 million1 Second tranche of $26 million proceeds from Additional non-dilutive resources anticipated PRV sale expected in January 2021 Projected cash use per quarter through 2020 ~ $6.5 to $7.5 million Shares outstanding as of
Slide 14: Lumos Pharma: Summary of Investment Thesis
Lumos Pharma: Summary of Investment Thesis Lumos Pharma • Lead program, LUM-201, with potential to be the (NASDAQ:LUMO) first oral growth hormone secretagogue therapy Transforming Lives for PGHD with Rare Focus • Opportunity to disrupt established and sizable market • Management team with extensive